Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | XPO1 | O14980 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | PHGDH | O43175 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.32 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27772576 | 1.00 | SMN1; SMN2 (0.41) | SMN1; SMN2MAPTNR2F2HTTXPO1 | |
| SCHEMBL966081 | 0.87 | CCNC (0.42) | SMN1; SMN2MAPTNR2F2HTTXPO1 | |
| SCHEMBL962500 | 0.86 | L3MBTL1 (0.50) | SMN1; SMN2MAPTNR2F2HTTL3MBTL1 | |
| SCHEMBL962501 | 0.86 | L3MBTL1 (0.50) | SMN1; SMN2MAPTNR2F2HTTL3MBTL1 | |
| SCHEMBL5111979 | 0.86 | SMN1; SMN2 (0.41) | SMN1; SMN2MAPTNR2F2HTTL3MBTL1 | |
| SCHEMBL962581 | 0.84 | SMN1; SMN2 (0.44) | SMN1; SMN2MAPTNR2F2HTTL3MBTL1 | |
| SCHEMBL962582 | 0.84 | SMN1; SMN2 (0.44) | SMN1; SMN2MAPTNR2F2HTTL3MBTL1 | |
| SCHEMBL963530 | 0.83 | HTT (0.41) | SMN1; SMN2MAPTNR2F2HTTL3MBTL1 | |
| SCHEMBL963533 | 0.83 | HTT (0.41) | SMN1; SMN2MAPTNR2F2HTTL3MBTL1 | |
| SCHEMBL5111983 | 0.81 | SMN1; SMN2 (0.41) | SMN1; SMN2MAPTNR2F2HTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-01-13 | — | — | US | disclosed |
| CN-101646653-A | Fused ring compounds as partial agonists of ppar-gamma | TAKEDA PHARMACEUTICAL JP | 2010-02-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | PPARA, PPARD, PPARG | SMN1; SMN2 4710/4885MAPT 4720/4885NR2F2 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.